Published in Blood on January 07, 2013
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med (2015) 1.74
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med (2013) 1.68
Activating STAT6 mutations in follicular lymphoma. Blood (2014) 1.63
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics (2014) 1.53
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood (2013) 1.17
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia (2013) 1.14
Fast and scalable inference of multi-sample cancer lineages. Genome Biol (2015) 1.13
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia (2014) 1.07
Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun (2014) 1.06
Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. Leukemia (2013) 1.05
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med (2015) 1.04
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A (2015) 1.03
Protein domain-level landscape of cancer-type-specific somatic mutations. PLoS Comput Biol (2015) 0.97
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol (2014) 0.96
High-dimensional single-cell cancer biology. Curr Top Microbiol Immunol (2014) 0.92
Early lesions of follicular lymphoma: a genetic perspective. Haematologica (2013) 0.92
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica (2015) 0.91
The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia (2014) 0.91
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood (2014) 0.90
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia (2016) 0.89
Genomic and epigenomic co-evolution in follicular lymphomas. Leukemia (2014) 0.88
Examining the impact of gene variants on histone lysine methylation. Biochim Biophys Acta (2014) 0.88
The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.88
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet (2015) 0.87
Nature and importance of follicular lymphoma precursors. Haematologica (2014) 0.85
Origin and migration of follicular lymphoma cells. Haematologica (2013) 0.83
Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood (2013) 0.83
Immunoglobulin gene repertoire diversification and selection in the stomach - from gastritis to gastric lymphomas. Front Immunol (2014) 0.82
Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J Exp Med (2014) 0.82
Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer J (2014) 0.82
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs (2015) 0.81
Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions. J Immunol (2014) 0.81
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica (2014) 0.80
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J (2015) 0.79
Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood (2016) 0.78
Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis. PLoS One (2014) 0.77
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. Sci Rep (2017) 0.76
High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution. PLoS One (2015) 0.76
Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission. Exp Hematol Oncol (2017) 0.75
Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies. J Transl Med (2016) 0.75
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia (2016) 0.75
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget (2017) 0.75
Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone. Case Rep Hematol (2016) 0.75
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. Clin Cancer Res (2016) 0.75
Genetic diversity of newly diagnosed follicular lymphoma. Blood Cancer J (2014) 0.75
SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing. BMC Genomics (2016) 0.75
MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma. Int J Clin Exp Pathol (2015) 0.75
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood (2016) 0.75
Epigenetic dysregulation in follicular lymphoma. Epigenomics (2015) 0.75
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb Mol Case Stud (2017) 0.75
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol (2017) 0.75
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Curr Treat Options Oncol (2017) 0.75
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
The life history of 21 breast cancers. Cell (2012) 10.59
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res (2009) 7.34
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res (2008) 6.91
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med (2012) 4.05
Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med (1987) 3.07
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol (2006) 1.70
Histone acetyl transferases as emerging drug targets. Drug Discov Today (2009) 1.64
Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood (2009) 1.64
IgTree: creating Immunoglobulin variable region gene lineage trees. J Immunol Methods (2008) 1.58
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood (2008) 1.36
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest (2006) 1.20
Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood (1991) 1.06
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov (2011) 1.02
Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Oncol Rep (2010) 0.99
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn (2007) 0.96
Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol (2004) 0.91
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol (2003) 0.89
Next-generation DNA sequencing. Nat Biotechnol (2008) 34.95
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res (2003) 10.28
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Precision and functional specificity in mRNA decay. Proc Natl Acad Sci U S A (2002) 8.20
Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96
Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences. Nature (2007) 7.91
Genome-wide analysis of mRNA translation profiles in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2003) 7.45
Histone variant H2A.Z marks the 5' ends of both active and inactive genes in euchromatin. Cell (2005) 7.20
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72
Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A (2003) 6.49
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Annotation, submission and screening of repetitive elements in Repbase: RepbaseSubmitter and Censor. BMC Bioinformatics (2006) 5.50
Global nucleosome occupancy in yeast. Genome Biol (2004) 5.49
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol (2011) 5.46
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci U S A (2007) 3.93
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci U S A (2002) 3.28
Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics (2006) 3.27
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell (2002) 3.21
Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum (2003) 3.05
Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology (2012) 2.98
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector. Nucleic Acids Res (2007) 2.70
Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol (2004) 2.69
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev (2009) 2.46
Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom (2010) 2.43
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res (2010) 2.25
Amino acid runs in eukaryotic proteomes and disease associations. Proc Natl Acad Sci U S A (2002) 2.17
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods (2007) 1.99
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99
The Stanford Tissue Microarray Database. Nucleic Acids Res (2007) 1.96
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood (2006) 1.94
Exosomes: Fit to deliver small RNA. Commun Integr Biol (2010) 1.93
Cell cycle- and chaperone-mediated regulation of H3K56ac incorporation in yeast. PLoS Genet (2008) 1.93
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood (2006) 1.93
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol (2008) 1.91
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (2007) 1.88
Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol (2005) 1.86
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood (2003) 1.73
Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma (2009) 1.68
Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray. J Clin Microbiol (2007) 1.67
Extracting binary signals from microarray time-course data. Nucleic Acids Res (2007) 1.67
Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks. PLoS One (2009) 1.66
Discovering biological progression underlying microarray samples. PLoS Comput Biol (2011) 1.65
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol (2002) 1.60
Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A (2012) 1.60
Characterization of early stages of human B cell development by gene expression profiling. J Immunol (2007) 1.60